TNFRSF9 and breast carcinoma: For example, a study by Priceman et al. compared CD137 CAR T cells and CD28 CAR T cells in treating HER2+ breast cancer and found that CD137 CAR T cells had improved tumor killing effects, with reduced T-cell exhaustion and greater proliferative capacity (Priceman et al., 2018).